Chen Shen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chen Shen has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Deze Li
Beijing Children‘s Hospital, China
34 shared publications - Hao Chen
Beijing Children‘s Hospital, China
28 shared publications Hao Chen
15 shared publicationsXiaotong Wang
National Center for Children’s Health, Beijing Children’s Hospital, Capital Medical University
12 shared publicationsDeze Li
Beijing Children’s Hospital
10 shared publications- Xiaotong Wang
Beijing Children‘s Hospital, China
10 shared publications
Latest Publications
- 14 November 2026
- Published by Springer Nature in Cytotechnology
- Vol. 78 (6)
A cross-study single-cell atlas reveals heterogeneous transcriptional states in PMA-differentiated THP-1 cells
- 14 November 2026
- Published by Springer Nature in Cytotechnology
- Vol. 78 (6)
A cross-study single-cell atlas reveals heterogeneous transcriptional states in PMA-differentiated THP-1 cells
- Open Access
- 12 November 2026
- Published by MDPI AG in Preprints.org
A Management Taxonomy in Etiologic Clothing: Why Pediatric Pleural Effusion Resists Classification
The conventional etiologic list for pediatric pleural effusion is a management taxonomy in etiologic clothing: its categories are bounded where treatment changes rather than where physiology changes, so mechanistic repairs keep failing. Effusion in children is a shared endpoint of mechanisms as distinct as parapneumonic inflammation, cardiac failure, hypoalbuminemia, malignant pleural involvement, thoracic duct disruption and trauma, yet most pediatric evidence comes from single-mechanism series and the list assigns each episode one label. We argue that single-label classification misrepresents the sign on three grounds. First, the four mechanistic routes — elevated hydrostatic pressure, reduced oncotic pressure, increased capillary permeability, impaired lymphatic clearance — are neither mutually exclusive nor independent: a permeability lesion rescales rather than adds to any concurrent pressure abnormality, and central venous pressure acts on both formation and clearance. Second, the transudate–exudate partition describes the capillary barrier, not the disease: an effusion is the time integral of formation minus clearance, so a single sample measures a stock asked to report a flow, and the inverse problem is underdetermined in principle; the partition was also derived in adults and requires fluid often never obtained in children. Third, effusions documented by imaging alone carry no mechanistic evidence, so complete classification is achievable only by imputation. We review pleural fluid homeostasis and its developmental features, Light's criteria and their pediatric limits, and the infectious and non-infectious mechanisms, then audit what the literature supports about the relative weight of each cause: published series are not comparable, and no multi-center pediatric series has characterized the full spectrum with a classification admitting simultaneous mechanisms and an explicit indeterminate category. We close by proposing — as a framework for evaluation, not a validated instrument — a three-level scheme whose mechanism axis is named for physiological route, admits simultaneous routes and an indeterminate category, carries an overlapping etiologic axis, and records fluid phenotypes as tags alongside mechanism rather than competing with it.
- 12 November 2026
- Published by MDPI AG in Preprints.org
Open AccessA Management Taxonomy in Etiologic Clothing: Why Pediatric Pleural Effusion Resists Classification
The conventional etiologic list for pediatric pleural effusion is a management taxonomy in etiologic clothing: its categories are bounded where treatment changes rather than where physiology changes, so mechanistic repairs keep failing. Effusion in children is a shared endpoint of mechanisms as distinct as parapneumonic inflammation, cardiac failure, hypoalbuminemia, malignant pleural involvement, thoracic duct disruption and trauma, yet most pediatric evidence comes from single-mechanism series and the list assigns each episode one label. We argue that single-label classification misrepresents the sign on three grounds. First, the four mechanistic routes — elevated hydrostatic pressure, reduced oncotic pressure, increased capillary permeability, impaired lymphatic clearance — are neither mutually exclusive nor independent: a permeability lesion rescales rather than adds to any concurrent pressure abnormality, and central venous pressure acts on both formation and clearance. Second, the transudate–exudate partition describes the capillary barrier, not the disease: an effusion is the time integral of formation minus clearance, so a single sample measures a stock asked to report a flow, and the inverse problem is underdetermined in principle; the partition was also derived in adults and requires fluid often never obtained in children. Third, effusions documented by imaging alone carry no mechanistic evidence, so complete classification is achievable only by imputation. We review pleural fluid homeostasis and its developmental features, Light's criteria and their pediatric limits, and the infectious and non-infectious mechanisms, then audit what the literature supports about the relative weight of each cause: published series are not comparable, and no multi-center pediatric series has characterized the full spectrum with a classification admitting simultaneous mechanisms and an explicit indeterminate category. We close by proposing — as a framework for evaluation, not a validated instrument — a three-level scheme whose mechanism axis is named for physiological route, admits simultaneous routes and an indeterminate category, carries an overlapping etiologic axis, and records fluid phenotypes as tags alongside mechanism rather than competing with it.
- Open Access
- 12 November 2026
- Published by MDPI AG in Preprints.org
Respiratory Haemophilus Influenzae in Henoch–Schönlein Purpura and Pneumonia: Capsular Type Associations in Children
Background. Haemophilus influenzae (Hi) is a common commensal of the pediatric respiratory tract and a lower-respiratory pathogen frequently detected in Henoch–Schönlein purpura (HSP, IgA vasculitis). Pathogenicity is largely capsule-determined, but the relationship between Hi capsular type and disease phenotype in children remains unclear. Methods. Detection rates were analyzed in a single-center cohort of 11,017 children who underwent bacterial nucleic-acid testing (HSP 2,596; other respiratory diseases 8,382; 39 with other respiratory diagnoses not entered into the comparisons), with 39 concurrently examined healthy children tested by the same assay as an external reference group. Hi-positive specimens were capsular-typed by an in-house two-step qPCR (bexA screening, then Region II multiplex, a–f). Associations were estimated by logistic regression with complementary age-confounding control and immune-status/testing-intensity sensitivity analyses; pathogenic potential was profiled in 44 reference genomes. Results. Hi detection was higher in HSP than in other respiratory diseases (57.0% vs 11.4%; adjusted OR 9.8, 95%CI 8.7–11.1) and healthy children (12.8%), consistent across age-handling methods and immune-normal subsets (ORs 7.8–9.8), and HSP-specific rather than severity-related. Capsular type spectra differed: HSP was relatively enriched for encapsulated type c (~50% vs 75–80% NTHi; OR 2.68–3.87). In pneumonia, NTHi patients were younger (median 3 vs 8 years) and more pneumonia-prone (74% vs 18%). Genomic pathogenic potential stratified by capsule; NTHi retained a rich virulence-factor repertoire. Conclusions. Respiratory Hi is highly detected in pediatric pneumonia and HSP, with distinct capsular type spectra and clear type–phenotype associations, consistent with capsule-dependent disease tropism. These associations are hypothesis-generating and require mechanistic validation.
- 12 November 2026
- Published by MDPI AG in Preprints.org
Open AccessRespiratory Haemophilus Influenzae in Henoch–Schönlein Purpura and Pneumonia: Capsular Type Associations in Children
Background. Haemophilus influenzae (Hi) is a common commensal of the pediatric respiratory tract and a lower-respiratory pathogen frequently detected in Henoch–Schönlein purpura (HSP, IgA vasculitis). Pathogenicity is largely capsule-determined, but the relationship between Hi capsular type and disease phenotype in children remains unclear. Methods. Detection rates were analyzed in a single-center cohort of 11,017 children who underwent bacterial nucleic-acid testing (HSP 2,596; other respiratory diseases 8,382; 39 with other respiratory diagnoses not entered into the comparisons), with 39 concurrently examined healthy children tested by the same assay as an external reference group. Hi-positive specimens were capsular-typed by an in-house two-step qPCR (bexA screening, then Region II multiplex, a–f). Associations were estimated by logistic regression with complementary age-confounding control and immune-status/testing-intensity sensitivity analyses; pathogenic potential was profiled in 44 reference genomes. Results. Hi detection was higher in HSP than in other respiratory diseases (57.0% vs 11.4%; adjusted OR 9.8, 95%CI 8.7–11.1) and healthy children (12.8%), consistent across age-handling methods and immune-normal subsets (ORs 7.8–9.8), and HSP-specific rather than severity-related. Capsular type spectra differed: HSP was relatively enriched for encapsulated type c (~50% vs 75–80% NTHi; OR 2.68–3.87). In pneumonia, NTHi patients were younger (median 3 vs 8 years) and more pneumonia-prone (74% vs 18%). Genomic pathogenic potential stratified by capsule; NTHi retained a rich virulence-factor repertoire. Conclusions. Respiratory Hi is highly detected in pediatric pneumonia and HSP, with distinct capsular type spectra and clear type–phenotype associations, consistent with capsule-dependent disease tropism. These associations are hypothesis-generating and require mechanistic validation.
- Open Access
- 6 November 2026
- Published by Springer Nature in Research Square
From Access to Appropriate Use: Reimbursement Design for Pathogen Nucleic Acid Diagnostics across Six Health Systems, 2014–2026
Background Pathogen nucleic acid diagnostics answer questions that culture, antigen detection and serology cannot answer within the treatment-decision window — slow-growing and fastidious organisms, paucibacillary disease, and genotypic resistance — yet are persistently reimbursed below that value; we ask whether that mismatch is transitional or structural. Methods We compare six health systems (China, the United States, Germany, France, England, Japan) under a most-different-systems design, tracing three index technology classes defined by target scope — single-pathogen detection with or without a resistance-conferring variant; multi-pathogen targeted detection by multiplex or isothermal amplification or panel enrichment with sequencing; and untargeted metagenomic sequencing of the primary specimen — through a three-gates framework (approval, price assignment, coverage) using primary policy documents, 2014–2026, under confidence-tiered verification. Results All six systems impose the same three gates, but the binding gate differs: China's price-item gate is being removed by the 2026 national price-item guideline (trial), which standardises item definitions but not price levels, so the binding constraint migrates to insurance listing rather than disappearing; the United States binds at clinical-utility evidence; Germany at coverage. A "double squeeze" of inpatient diagnosis-related-group bundling and outpatient price compression (Medicare's ratcheted PAMA repricing, repeatedly deferred; China's volume-based procurement cuts of 47–77%; Japan's FY2014 256-item fee cut) suppresses adoption of cost-effective tests. Five innovation carve-outs echoing the coverage-with-evidence-development concept underperform for diagnostics: Germany's inpatient innovation channel (NUB) integrated 105 of more than 3,400 methods into regular payment in 2005–2020 (single peer-reviewed source); Medicare's molecular-panel coverage policy excludes metagenomic sequencing from its scope, with no affirmative coverage elsewhere. Regulatory review itself ranges from months (Japan's targets; US 510(k) goals) to multiple years (China's Class III elapsed times; EU notified-body backlogs). For metagenomic sequencing, Gate 1 is a laboratory-accreditation regime rather than product review, and the longest lags sit at the approval–payment interface (median 5.7 years from FDA authorisation to nominal Medicare coverage in a 2016–2019 cohort; diagnostics' lags were shorter). Conclusion The reimbursement gap is structural and is best explained by the externalisation of diagnostic value across budget silos; closing it requires diagnostic-specific payment design coupled to prescriber competency in test selection.
- 6 November 2026
- Published by Springer Nature in Research Square
Open AccessFrom Access to Appropriate Use: Reimbursement Design for Pathogen Nucleic Acid Diagnostics across Six Health Systems, 2014–2026
Background Pathogen nucleic acid diagnostics answer questions that culture, antigen detection and serology cannot answer within the treatment-decision window — slow-growing and fastidious organisms, paucibacillary disease, and genotypic resistance — yet are persistently reimbursed below that value; we ask whether that mismatch is transitional or structural. Methods We compare six health systems (China, the United States, Germany, France, England, Japan) under a most-different-systems design, tracing three index technology classes defined by target scope — single-pathogen detection with or without a resistance-conferring variant; multi-pathogen targeted detection by multiplex or isothermal amplification or panel enrichment with sequencing; and untargeted metagenomic sequencing of the primary specimen — through a three-gates framework (approval, price assignment, coverage) using primary policy documents, 2014–2026, under confidence-tiered verification. Results All six systems impose the same three gates, but the binding gate differs: China's price-item gate is being removed by the 2026 national price-item guideline (trial), which standardises item definitions but not price levels, so the binding constraint migrates to insurance listing rather than disappearing; the United States binds at clinical-utility evidence; Germany at coverage. A "double squeeze" of inpatient diagnosis-related-group bundling and outpatient price compression (Medicare's ratcheted PAMA repricing, repeatedly deferred; China's volume-based procurement cuts of 47–77%; Japan's FY2014 256-item fee cut) suppresses adoption of cost-effective tests. Five innovation carve-outs echoing the coverage-with-evidence-development concept underperform for diagnostics: Germany's inpatient innovation channel (NUB) integrated 105 of more than 3,400 methods into regular payment in 2005–2020 (single peer-reviewed source); Medicare's molecular-panel coverage policy excludes metagenomic sequencing from its scope, with no affirmative coverage elsewhere. Regulatory review itself ranges from months (Japan's targets; US 510(k) goals) to multiple years (China's Class III elapsed times; EU notified-body backlogs). For metagenomic sequencing, Gate 1 is a laboratory-accreditation regime rather than product review, and the longest lags sit at the approval–payment interface (median 5.7 years from FDA authorisation to nominal Medicare coverage in a 2016–2019 cohort; diagnostics' lags were shorter). Conclusion The reimbursement gap is structural and is best explained by the externalisation of diagnostic value across budget silos; closing it requires diagnostic-specific payment design coupled to prescriber competency in test selection.
- Open Access
- 6 November 2026
- Published by MDPI AG in Preprints.org
Global and Super-Regional Burden of Mycoplasma pneumoniae–Attributable Lower Respiratory Infection Deaths in Children Aged 0–19 Years, 1990–2023: A Systematic Analysis of the Global Burden of Disease Study 2023
Background. Mycoplasma pneumoniae, the archetypal agent of “walking pneumonia”, causes predominantly self-limited infection peaking in school-age children and adolescents, and is regarded as rarely fatal. After near-disappearance under pandemic non-pharmaceutical interventions in 2020–2021, re-emergence was delayed relative to other respiratory pathogens but was well established by 2023–2024. No standalone global estimate of M. pneumoniae–attributable mortality spanning the pandemic window has been reported to contextualise this resurgence. Methods. We analysed Global Burden of Disease (GBD) Study 2023 estimates (release v8352), which attribute lower respiratory infection (LRI) deaths to 26 pathogens through a counterfactual, population-attributable-fraction framework. Attributable deaths (the only available measure) were extracted globally and for seven super-regions, 1990–2023, for children aged 0–19 years (under 5, 5–9, 10–14, and 15–19 years). Trends were summarised by estimated annual percentage change (EAPC); 95% uncertainty intervals (UIs) were propagated conservatively. Reporting follows the GATHER statement. Results. In 2023, an estimated 26,382 deaths (95% UI 18,984–36,012) in children aged 0–19 years were attributable to M. pneumoniae, ranking ninth among 26 LRI aetiologies and accounting for 3.71% of all-pathogen LRI deaths. Deaths fell by 50.7% from 1990 to 2023 (EAPC −2.45% per year, 95% CI −2.66 to −2.23). Sub-Saharan Africa and South Asia carried 81.6% of the 2023 total. The 5–14 year share of attributable deaths was 15.0%, versus 2.2% for respiratory syncytial virus. Children under 5 years accounted for 80.6% of attributable deaths. Across the pandemic window, deaths fell only 17.1% in 2019–2021—versus 62.6% for influenza and 65.2% for respiratory syncytial virus—then rebounded 16.1% by 2023, exceeding the no-pandemic trend extrapolation by 19.2%. The crude mortality rate fell faster than counts (EAPC −2.93% per year), and estimates were stable across GBD rounds (≤2.6% difference for under-5 deaths).Conclusions. Modelled M. pneumoniae mortality concentrates where macrolide-resistance data and diagnostics are scarcest; its school-age skew and post-pandemic rebound are coherent with surveillance. These estimates provide baselines for age-targeted empirical-treatment guidance and resistance-aware stewardship.
- 6 November 2026
- Published by MDPI AG in Preprints.org
Open AccessGlobal and Super-Regional Burden of Mycoplasma pneumoniae–Attributable Lower Respiratory Infection Deaths in Children Aged 0–19 Years, 1990–2023: A Systematic Analysis of the Global Burden of Disease Study 2023
Background. Mycoplasma pneumoniae, the archetypal agent of “walking pneumonia”, causes predominantly self-limited infection peaking in school-age children and adolescents, and is regarded as rarely fatal. After near-disappearance under pandemic non-pharmaceutical interventions in 2020–2021, re-emergence was delayed relative to other respiratory pathogens but was well established by 2023–2024. No standalone global estimate of M. pneumoniae–attributable mortality spanning the pandemic window has been reported to contextualise this resurgence. Methods. We analysed Global Burden of Disease (GBD) Study 2023 estimates (release v8352), which attribute lower respiratory infection (LRI) deaths to 26 pathogens through a counterfactual, population-attributable-fraction framework. Attributable deaths (the only available measure) were extracted globally and for seven super-regions, 1990–2023, for children aged 0–19 years (under 5, 5–9, 10–14, and 15–19 years). Trends were summarised by estimated annual percentage change (EAPC); 95% uncertainty intervals (UIs) were propagated conservatively. Reporting follows the GATHER statement. Results. In 2023, an estimated 26,382 deaths (95% UI 18,984–36,012) in children aged 0–19 years were attributable to M. pneumoniae, ranking ninth among 26 LRI aetiologies and accounting for 3.71% of all-pathogen LRI deaths. Deaths fell by 50.7% from 1990 to 2023 (EAPC −2.45% per year, 95% CI −2.66 to −2.23). Sub-Saharan Africa and South Asia carried 81.6% of the 2023 total. The 5–14 year share of attributable deaths was 15.0%, versus 2.2% for respiratory syncytial virus. Children under 5 years accounted for 80.6% of attributable deaths. Across the pandemic window, deaths fell only 17.1% in 2019–2021—versus 62.6% for influenza and 65.2% for respiratory syncytial virus—then rebounded 16.1% by 2023, exceeding the no-pandemic trend extrapolation by 19.2%. The crude mortality rate fell faster than counts (EAPC −2.93% per year), and estimates were stable across GBD rounds (≤2.6% difference for under-5 deaths).Conclusions. Modelled M. pneumoniae mortality concentrates where macrolide-resistance data and diagnostics are scarcest; its school-age skew and post-pandemic rebound are coherent with surveillance. These estimates provide baselines for age-targeted empirical-treatment guidance and resistance-aware stewardship.
- Open Access
- 5 November 2026
- Published by MDPI AG in Preprints.org
An Interferon-Braked Monocyte State and Compartment-Specific Myeloid Programming Across Severe Respiratory Infections
Severe COVID-19 is accompanied by marked remodeling of airway myeloid compartments, yet how infiltrating monocytes are routed toward inflammatory versus pro-fibrotic fates, and why resident alveolar macrophages fail to recover, remains incompletely understood. We re-analyzed BALF single-cell data (GSE145926; 3 healthy, 3 mild/moderate, 6 severe; 27,807 cells), re-clustering myeloid cells (n = 19,485) into 37 fine states (13 families) with functional module scoring, diffusion pseudotime, PAGA, a curated ligand–receptor screen, and per-donor decomposition; validation used the independent fatal-COVID-19 BALF cohort GSE157344 and the healthy-BALF cohort GSE151928 as a specificity control, a human endotoxin bone-marrow comparator (GSE212092), two sepsis blood cohorts (GSE175453; GSE167363, paired 0 h/6 h), three cross-pathogen blood cohorts (influenza A GSE243629, infant RSV GSE283746, bacterial ARDS GSE157789), and cross-disease comparison with IPF lung (GSE128033). Healthy BALF comprised resident alveolar macrophages, depleted in severe disease and replaced by interferon-activated, CXCL8-high, and SPP1+ populations. A CD14+SPP1−FCN1+ population co-expressing interferon-stimulated genes and IL1RN—an interferon-braked state distinct from LPS-type trained immunity—was enriched in severe disease, driven predominantly by one patient. PAGA delineated an FCN1+→intermediate→SPP1+ continuum; severe-enriched circuits included MIF–CD74 and an autocrine CXCL8–CXCR2 loop. The interferon-braked signature and SPP1+ compartments were reproduced in an independent fatal-COVID-19 BALF cohort and were at baseline in a healthy-BALF reference cohort (0.343 ± 0.091); LPS-challenged marrow showed the reciprocal pattern (TLR4-high, interferon-silent); and IPF lung shared SPP1/TREM2 induction with resident-AM collapse (SPP1 p = 0.0005). In sepsis blood, monocytes retained the interferon-braked signature with the LPS/TLR4 module near baseline; the signature was likewise elevated in bacterial ARDS, influenza A, and infant RSV monocytes, extending the compartment model beyond COVID-19. The data support a two-signal model: interferon restrains recruited monocytes at entry, while TLR4/HIF-1α- and SPP1-associated programs act downstream. The brake state is a measurable, stage-specific marker; MIF–CD74, CXCL8–CXCR2, and SPP1–CD44 are candidate nodes for stage-specific intervention. These mechanistic interpretations are grounded in the data and are proposed as testable hypotheses.
- 5 November 2026
- Published by MDPI AG in Preprints.org
Open AccessAn Interferon-Braked Monocyte State and Compartment-Specific Myeloid Programming Across Severe Respiratory Infections
Severe COVID-19 is accompanied by marked remodeling of airway myeloid compartments, yet how infiltrating monocytes are routed toward inflammatory versus pro-fibrotic fates, and why resident alveolar macrophages fail to recover, remains incompletely understood. We re-analyzed BALF single-cell data (GSE145926; 3 healthy, 3 mild/moderate, 6 severe; 27,807 cells), re-clustering myeloid cells (n = 19,485) into 37 fine states (13 families) with functional module scoring, diffusion pseudotime, PAGA, a curated ligand–receptor screen, and per-donor decomposition; validation used the independent fatal-COVID-19 BALF cohort GSE157344 and the healthy-BALF cohort GSE151928 as a specificity control, a human endotoxin bone-marrow comparator (GSE212092), two sepsis blood cohorts (GSE175453; GSE167363, paired 0 h/6 h), three cross-pathogen blood cohorts (influenza A GSE243629, infant RSV GSE283746, bacterial ARDS GSE157789), and cross-disease comparison with IPF lung (GSE128033). Healthy BALF comprised resident alveolar macrophages, depleted in severe disease and replaced by interferon-activated, CXCL8-high, and SPP1+ populations. A CD14+SPP1−FCN1+ population co-expressing interferon-stimulated genes and IL1RN—an interferon-braked state distinct from LPS-type trained immunity—was enriched in severe disease, driven predominantly by one patient. PAGA delineated an FCN1+→intermediate→SPP1+ continuum; severe-enriched circuits included MIF–CD74 and an autocrine CXCL8–CXCR2 loop. The interferon-braked signature and SPP1+ compartments were reproduced in an independent fatal-COVID-19 BALF cohort and were at baseline in a healthy-BALF reference cohort (0.343 ± 0.091); LPS-challenged marrow showed the reciprocal pattern (TLR4-high, interferon-silent); and IPF lung shared SPP1/TREM2 induction with resident-AM collapse (SPP1 p = 0.0005). In sepsis blood, monocytes retained the interferon-braked signature with the LPS/TLR4 module near baseline; the signature was likewise elevated in bacterial ARDS, influenza A, and infant RSV monocytes, extending the compartment model beyond COVID-19. The data support a two-signal model: interferon restrains recruited monocytes at entry, while TLR4/HIF-1α- and SPP1-associated programs act downstream. The brake state is a measurable, stage-specific marker; MIF–CD74, CXCL8–CXCR2, and SPP1–CD44 are candidate nodes for stage-specific intervention. These mechanistic interpretations are grounded in the data and are proposed as testable hypotheses.
- Open Access
- 5 November 2026
- Published by MDPI AG in Preprints.org
No Spatially Resolvable Perivascular Monocyte Gradient in Healthy Human Lung: A Spatial-Transcriptomic Test of the Sustained-Extravasation Model of Interstitial Macrophage Renewal
Background: Whether lung interstitial macrophages (IMs) are continuously replenished by blood-monocyte extravasation remains unresolved. We performed a hypothesis-driven secondary analysis of four public datasets. Methods: Dual-module scoring (MonoScore/ResidScore) was combined with vessel-distance gradient tests across the Madissoon 2023 healthy-lung atlas, the 10x PBMC 10k reference, and the Natri 2024 lung-disease cohort, using donor or slide as the statistical unit, spatially aware permutation nulls, and multiple-testing correction. Results: Among 40,634 healthy lung myeloid cells (34,912 in six axis populations), a continuous monocyte-to-resident axis placed perivascular IMs at the resident pole; batch-free intra-lung controls separated lung CD14 monocytes from perivascular IMs (AUC=0.9924), whereas cross-dataset AUCs are batch-confounded upper bounds not used for inference. Across three Visium slides (two donors), ResidScore signal per spot rose with vessel distance (3/3 slides concordant; toroidal-shift p=0.009-0.016, not surviving Bonferroni correction), while no slide showed the predicted monocyte-signal decay; block-level intervals were uninformative. In idiopathic pulmonary fibrosis (IPF), IM MonoScore was elevated (+0.088, p_adj=0.014 across 36 tests) without significant ResidScore loss or compositional change (p=0.68). Conclusions: This cross-sectional design cannot test ontogeny; it tests the spatial corollary of sustained extravasation, which steady-state adult human lung does not support — without contradicting mouse fate-mapping evidence, which addresses developmental and turnover-level origin. The perivascular niche emerges as a candidate renewal interface with a locally attenuated residency program. In IPF, IM monocytization reflects transcriptional reprogramming rather than compositional replacement.
- 5 November 2026
- Published by MDPI AG in Preprints.org
Open AccessNo Spatially Resolvable Perivascular Monocyte Gradient in Healthy Human Lung: A Spatial-Transcriptomic Test of the Sustained-Extravasation Model of Interstitial Macrophage Renewal
Background: Whether lung interstitial macrophages (IMs) are continuously replenished by blood-monocyte extravasation remains unresolved. We performed a hypothesis-driven secondary analysis of four public datasets. Methods: Dual-module scoring (MonoScore/ResidScore) was combined with vessel-distance gradient tests across the Madissoon 2023 healthy-lung atlas, the 10x PBMC 10k reference, and the Natri 2024 lung-disease cohort, using donor or slide as the statistical unit, spatially aware permutation nulls, and multiple-testing correction. Results: Among 40,634 healthy lung myeloid cells (34,912 in six axis populations), a continuous monocyte-to-resident axis placed perivascular IMs at the resident pole; batch-free intra-lung controls separated lung CD14 monocytes from perivascular IMs (AUC=0.9924), whereas cross-dataset AUCs are batch-confounded upper bounds not used for inference. Across three Visium slides (two donors), ResidScore signal per spot rose with vessel distance (3/3 slides concordant; toroidal-shift p=0.009-0.016, not surviving Bonferroni correction), while no slide showed the predicted monocyte-signal decay; block-level intervals were uninformative. In idiopathic pulmonary fibrosis (IPF), IM MonoScore was elevated (+0.088, p_adj=0.014 across 36 tests) without significant ResidScore loss or compositional change (p=0.68). Conclusions: This cross-sectional design cannot test ontogeny; it tests the spatial corollary of sustained extravasation, which steady-state adult human lung does not support — without contradicting mouse fate-mapping evidence, which addresses developmental and turnover-level origin. The perivascular niche emerges as a candidate renewal interface with a locally attenuated residency program. In IPF, IM monocytization reflects transcriptional reprogramming rather than compositional replacement.
- Open Access
- 5 November 2026
- Published by MDPI AG in Preprints.org
CD10/Neprilysin as an Integrated Transcriptional Readout of Alveolar Macrophage Homeostatic Identity: A Multi-Dataset Secondary Analysis
Background. Alveolar macrophages (AMs) are long-lived resident sentinels of the alveolar lumen. Yet no single surface readout coupled to their homeostatic program, with an explicit interpretation rule in disease, has been consolidated. CD10 (MME/neprilysin) is listed among human AM surface markers, but its performance as an identity readout and its biology have not been characterized across datasets, programs and disease states. We asked whether CD10 marks AM homeostatic identity, which programs it couples to, and how it changes in disease. Methods. We performed a secondary analysis of the Madissoon healthy human lung atlas and the Natri lung-disease atlas, with bronchoalveolar lavage (BAL) studies as literature-level reference. We quantified MME detection across compartments, co-expression programs, MME+/MME− dichotomized comparisons with sequencing-depth-matched controls, and donor-level disease statistics using the donor as the statistical unit. Results. CD10 marked resident AMs: MME was detected in 30.1% of AMs and 51.9% of proliferating AMs, versus 0.2–0.3% of monocytes. Within AMs, higher MME tracked the PPARγ lipid and TGFβ maturation programs (Pearson ρ = 0.296 with ITGB8, ρ = 0.209 with PPARG) together with a don’t-eat-me profile (3.20-fold PD-L1, 1.39-fold CD47); these couplings survived sequencing-depth-matched controls. At donor level, the MME–FABP4 coupling was reproduced (ρ = 0.472) whereas MME–PPARG was not. AM-compartment MME did not differ between idiopathic pulmonary fibrosis (IPF) and control (p = 0.92; 36 versus 44 donors), and no AM-compartment change survived FDR control in any diagnosis, whereas interstitial macrophage MME increased in IPF (p = 0.0003, FDR = 0.003) and non-IPF interstitial lung disease (p = 0.0042, FDR = 0.023). Conclusions. CD10 is a transcript-level candidate readout of AM homeostatic identity, co-expressed with the PPARγ lipid program and elevated don’t-eat-me signals. Disease-associated changes are compartment-specific, stable within AMs and induced within interstitial macrophages, consistent with compartment remodelling rather than wholesale loss; measured on tissue composition, dilution alone predicts that AM-dependent samples lose roughly half of their CD10 signal in fibrosis, quantitatively matching prior reports of resident AM depletion. Protein-level validation is pending.
- 5 November 2026
- Published by MDPI AG in Preprints.org
Open AccessCD10/Neprilysin as an Integrated Transcriptional Readout of Alveolar Macrophage Homeostatic Identity: A Multi-Dataset Secondary Analysis
Background. Alveolar macrophages (AMs) are long-lived resident sentinels of the alveolar lumen. Yet no single surface readout coupled to their homeostatic program, with an explicit interpretation rule in disease, has been consolidated. CD10 (MME/neprilysin) is listed among human AM surface markers, but its performance as an identity readout and its biology have not been characterized across datasets, programs and disease states. We asked whether CD10 marks AM homeostatic identity, which programs it couples to, and how it changes in disease. Methods. We performed a secondary analysis of the Madissoon healthy human lung atlas and the Natri lung-disease atlas, with bronchoalveolar lavage (BAL) studies as literature-level reference. We quantified MME detection across compartments, co-expression programs, MME+/MME− dichotomized comparisons with sequencing-depth-matched controls, and donor-level disease statistics using the donor as the statistical unit. Results. CD10 marked resident AMs: MME was detected in 30.1% of AMs and 51.9% of proliferating AMs, versus 0.2–0.3% of monocytes. Within AMs, higher MME tracked the PPARγ lipid and TGFβ maturation programs (Pearson ρ = 0.296 with ITGB8, ρ = 0.209 with PPARG) together with a don’t-eat-me profile (3.20-fold PD-L1, 1.39-fold CD47); these couplings survived sequencing-depth-matched controls. At donor level, the MME–FABP4 coupling was reproduced (ρ = 0.472) whereas MME–PPARG was not. AM-compartment MME did not differ between idiopathic pulmonary fibrosis (IPF) and control (p = 0.92; 36 versus 44 donors), and no AM-compartment change survived FDR control in any diagnosis, whereas interstitial macrophage MME increased in IPF (p = 0.0003, FDR = 0.003) and non-IPF interstitial lung disease (p = 0.0042, FDR = 0.023). Conclusions. CD10 is a transcript-level candidate readout of AM homeostatic identity, co-expressed with the PPARγ lipid program and elevated don’t-eat-me signals. Disease-associated changes are compartment-specific, stable within AMs and induced within interstitial macrophages, consistent with compartment remodelling rather than wholesale loss; measured on tissue composition, dilution alone predicts that AM-dependent samples lose roughly half of their CD10 signal in fibrosis, quantitatively matching prior reports of resident AM depletion. Protein-level validation is pending.
- Open Access
- 5 November 2026
- Published by MDPI AG in Preprints.org
Spatially Resolved Immunometabolic Reprogramming of Tumor-Associated Macrophages: An Integrative Multi-Layer Re-Analysis of Public Spatial Metabolomics, Spatial Transcriptomics and Single-Cell Resources
Background: Metabolic reprogramming of tumor-associated macrophages (TAMs) drives tumor immune evasion, yet the spatial and subtype-level organization of TAM metabolism remains under-characterized. Methods: We re-analyzed public spatial metabolomics, spatial transcriptomics, and single-cell datasets using autocorrelation-corrected spatial statistics, patient-level testing, and replication across breast, lung, colorectal, liver, and brain tumor data. Results: TAMs formed the most spatially clustered transcriptional module in breast tumor sections. TAM-dense regions were robustly coupled to iron handling (ρ = 0.568), surviving gene-overlap, cell-abundance, and erythrocyte/vascular-exposure controls, whereas apparent glycolysis and lipid-uptake links did not survive spatial or abundance correction. In lung adenocarcinoma, subtype comparisons were confounded by tissue origin; within tumor tissue, two differences persisted across patients (higher lipid uptake in C1QC⁺ and higher iron handling in FOLR2⁺ TAMs). A reported SPP1⁺-versus-C1QC⁺ polarity recurred at cell level across cancer types but not at patient level. Mitochondrial DNA tracing detected clonally expanded, metabolically hyperactive TAMs in two of four evaluable samples. Conclusions: TAM metabolism is spatially organized and subtype-specific, with iron handling as the most robust territorial coupling, supporting spatially stratified, subtype-aware design of metabolism-targeting trials.
- 5 November 2026
- Published by MDPI AG in Preprints.org
Open AccessSpatially Resolved Immunometabolic Reprogramming of Tumor-Associated Macrophages: An Integrative Multi-Layer Re-Analysis of Public Spatial Metabolomics, Spatial Transcriptomics and Single-Cell Resources
Background: Metabolic reprogramming of tumor-associated macrophages (TAMs) drives tumor immune evasion, yet the spatial and subtype-level organization of TAM metabolism remains under-characterized. Methods: We re-analyzed public spatial metabolomics, spatial transcriptomics, and single-cell datasets using autocorrelation-corrected spatial statistics, patient-level testing, and replication across breast, lung, colorectal, liver, and brain tumor data. Results: TAMs formed the most spatially clustered transcriptional module in breast tumor sections. TAM-dense regions were robustly coupled to iron handling (ρ = 0.568), surviving gene-overlap, cell-abundance, and erythrocyte/vascular-exposure controls, whereas apparent glycolysis and lipid-uptake links did not survive spatial or abundance correction. In lung adenocarcinoma, subtype comparisons were confounded by tissue origin; within tumor tissue, two differences persisted across patients (higher lipid uptake in C1QC⁺ and higher iron handling in FOLR2⁺ TAMs). A reported SPP1⁺-versus-C1QC⁺ polarity recurred at cell level across cancer types but not at patient level. Mitochondrial DNA tracing detected clonally expanded, metabolically hyperactive TAMs in two of four evaluable samples. Conclusions: TAM metabolism is spatially organized and subtype-specific, with iron handling as the most robust territorial coupling, supporting spatially stratified, subtype-aware design of metabolism-targeting trials.
- Open Access
- 4 November 2026
- Published by MDPI AG in Preprints.org
Maternal Protection and Pathogen-Specific Humoral and Cellular Immunity Explain the Age-Specific Spectrum of Respiratory Infections in Children and Adults: A Mechanistic Synthesis
Respiratory pathogens infect children in a reproducible age order: respiratory syncytial virus (RSV) and pertussis dominate the first months of life, human bocavirus and adenovirus peak in toddlers, Mycoplasma pneumoniae pneumonia peaks at school age, rhinovirus and influenza infect all ages, and several of these pathogens resurge in older adults. Here we compile and organize the published evidence behind these patterns, treating each pathogen’s characteristic age window as a read-out of its immune mechanism within the classical age-structured tradition. Two interacting “clocks” organize the pediatric spectrum. The first is the maternal-antibody umbrella: transplacental IgG decays by infant catabolism, and the protective trough at 2–6 months is set by the distance between the starting titer and a protective threshold, measured in half-lives, rather than by any single half-life; maternal RSVpreF and Tdap vaccination and passive nirsevimab prophylaxis provide trial-level causal proof that this clock sets the infant window. The second clock is the cumulative acquisition of type-specific immunity, which closes the toddler windows of bocavirus and adenovirus but never closes for antigenically diverse rhinovirus or drifting influenza; since exposure accumulates on a similar schedule, this clock is only partially identifiable serologically. M. pneumoniae is the decisive boundary case: a single maternal clock under a constant force of infection cannot place a peak at school age—a known structural property of age-structured transmission models, no new simulations performed—so delayed first sensitization, waning partial immunity, and immunopathology on reinfection are required. For encapsulated bacteria, a “polysaccharide trap”—poorly transferred IgG2-dominated maternal antibody plus developmental T-independent unresponsiveness before age two—explains the earliest bacterial windows. We also synthesize breast-milk, innate-immune and microbiome modifiers of both clocks, and an adult “third clock” of immunosenescence. The framework yields falsifiable predictions for immunization timing and disease patterns in immunocompromised hosts.
- 4 November 2026
- Published by MDPI AG in Preprints.org
Open AccessMaternal Protection and Pathogen-Specific Humoral and Cellular Immunity Explain the Age-Specific Spectrum of Respiratory Infections in Children and Adults: A Mechanistic Synthesis
Respiratory pathogens infect children in a reproducible age order: respiratory syncytial virus (RSV) and pertussis dominate the first months of life, human bocavirus and adenovirus peak in toddlers, Mycoplasma pneumoniae pneumonia peaks at school age, rhinovirus and influenza infect all ages, and several of these pathogens resurge in older adults. Here we compile and organize the published evidence behind these patterns, treating each pathogen’s characteristic age window as a read-out of its immune mechanism within the classical age-structured tradition. Two interacting “clocks” organize the pediatric spectrum. The first is the maternal-antibody umbrella: transplacental IgG decays by infant catabolism, and the protective trough at 2–6 months is set by the distance between the starting titer and a protective threshold, measured in half-lives, rather than by any single half-life; maternal RSVpreF and Tdap vaccination and passive nirsevimab prophylaxis provide trial-level causal proof that this clock sets the infant window. The second clock is the cumulative acquisition of type-specific immunity, which closes the toddler windows of bocavirus and adenovirus but never closes for antigenically diverse rhinovirus or drifting influenza; since exposure accumulates on a similar schedule, this clock is only partially identifiable serologically. M. pneumoniae is the decisive boundary case: a single maternal clock under a constant force of infection cannot place a peak at school age—a known structural property of age-structured transmission models, no new simulations performed—so delayed first sensitization, waning partial immunity, and immunopathology on reinfection are required. For encapsulated bacteria, a “polysaccharide trap”—poorly transferred IgG2-dominated maternal antibody plus developmental T-independent unresponsiveness before age two—explains the earliest bacterial windows. We also synthesize breast-milk, innate-immune and microbiome modifiers of both clocks, and an adult “third clock” of immunosenescence. The framework yields falsifiable predictions for immunization timing and disease patterns in immunocompromised hosts.